Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB

Peter T. Nelson, Richard J. Kryscio, Erin L. Abner, Frederick A. Schmitt, Gregory A. Jicha, Marta S. Mendiondo, Greg Cooper, Charles B. Smith, William R. Markesbery

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Dementia can be caused by different diseases including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = 5) or patients that were profoundly demented at recruitment (intake MMSE < 20; n = 86) were excluded to strengthen our ability to test the association of specific clinical and pathological indices. Patients with pathologically-diagnosed AD + DLB (n = 25) lost cognitive capacity faster than patients with AD alone (n = 40). In both diseases, treatment with acetylcholinesterase inhibitors was associated with a slower rate of cognitive decline.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalJournal of Alzheimer's Disease
Volume16
Issue number1
DOIs
StatePublished - 2009

Keywords

  • Acetycholinesterase
  • Acetylcholinesterase inhibitors
  • Alzheimer's disease
  • Cholinesterase
  • Dementia with Lewy bodies
  • Neuropathology

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer's disease and AD + DLB'. Together they form a unique fingerprint.

Cite this